U.S. markets open in 4 hours 23 minutes
  • S&P Futures

    4,347.00
    +21.50 (+0.50%)
     
  • Dow Futures

    33,861.00
    +136.00 (+0.40%)
     
  • Nasdaq Futures

    14,969.25
    +102.75 (+0.69%)
     
  • Russell 2000 Futures

    1,807.00
    +8.40 (+0.47%)
     
  • Crude Oil

    91.04
    +0.25 (+0.28%)
     
  • Gold

    1,855.60
    -10.50 (-0.56%)
     
  • Silver

    21.94
    -0.51 (-2.25%)
     
  • EUR/USD

    1.0555
    -0.0020 (-0.19%)
     
  • 10-Yr Bond

    4.5730
    0.0000 (0.00%)
     
  • Vix

    17.42
    -0.10 (-0.57%)
     
  • GBP/USD

    1.2181
    -0.0019 (-0.16%)
     
  • USD/JPY

    149.6730
    +0.3430 (+0.23%)
     
  • Bitcoin USD

    28,320.11
    +1,165.55 (+4.29%)
     
  • CMC Crypto 200

    607.59
    +28.83 (+4.98%)
     
  • FTSE 100

    7,610.26
    +2.18 (+0.03%)
     
  • Nikkei 225

    31,759.88
    -97.72 (-0.31%)
     

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

Zevra Therapeutics
Zevra Therapeutics

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.

The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company’s website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023.

Additionally, interested participants and investors may access the conference call by dialing either:

  • (800) 343-4849 (U.S.)

  • +1 (203) 518-9848 (International)

  • Conference ID: ZVRAQ422

About Zevra

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, regulatory, and commercialization strategies, the Company is overcoming complex drug development challenges to bring much-needed therapies to patients.

Contacts

Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com

Jennifer Arcure
+1 (917) 603-0681
Jennifer.arcure@evokegroup.com